Psychedelics: What Experts Say on Microdosing

Microdosing has become the friendly face of the psychedelic revival, a few micrograms of psilocybin or LSD folded into a normal working day, no visions required. The promise is subtle: more focus, more creativity, a lighter mood, with none of the intensity of a full trip. It sounds almost too convenient, so it is worth checking what the researchers who actually run the trials have said when they sat down with these podcast hosts.

The picture that emerges from Andrew Huberman, Joe Rogan, and The Diary of a CEO is split. On microdosing specifically, the experts are cool to skeptical. On full, guided, high doses for particular conditions, several are cautiously optimistic. Here are the concrete claims, each with a timestamp so you can hear the source and judge for yourself.

The single most direct claim in the material comes from psychedelic researcher Matthew Johnson on Huberman Lab. Johnson states there is no credible peer reviewed evidence that microdosing works, and that the studies run the range from no effect at all to slight cognitive impairment. That is a striking thing to hear from someone who has spent years studying these compounds and clearly believes in their clinical potential.

It is not an isolated opinion. On Huberman's conversation with Dacher Keltner, the data from Robin Carhart-Harris are described the same way: no benefit from microdosing on major depression when measured against two guided psilocybin sessions. In other words, the version of psychedelics that asks the least of you appears to deliver the least. The action, if there is any, seems to live in the full experience rather than the sprinkle.

When the conversation shifts to full, supervised sessions, the tone changes. On Huberman Lab, psychiatrist Paul Conti argues that psychedelics used clinically are powerful anti trauma tools, quieting the cortical chatter of the outer brain and seating consciousness in deeper regions where change can take hold. The framing is therapeutic and deliberate, a long way from a casual daily dose.

Some of the numbers cited are dramatic. On Joe Rogan's episode with Sarko Gergerian, psilocybin is cited as having roughly an eighty percent success rate against opioid use disorder after a single experience, climbing into the high nineties after two. And on the addiction question itself, Dr. Keith Humphreys tells Huberman there is essentially no evidence that psilocybin or LSD are addictive, describing their abuse potential as extremely slight. Those claims deserve scrutiny rather than blind trust, but they explain why serious clinicians keep studying the full dose model.

Part of the intrigue is mechanistic. On the episode with Nolan Williams, Huberman relays a finding from Carhart-Harris and Nutt that surprised the researchers themselves: psychedelics decrease overall brain activity while increasing global connectivity, the opposite of the lit up brain many people picture. Regions that normally do not talk to each other suddenly do.

The chemistry is more settled than the folklore suggests. Matthew Johnson notes that all classic psychedelics act as agonists or partial agonists at the serotonin 2A receptor, a single shared doorway into the nervous system. He also points out that psilocybin occurs naturally in over two hundred known species of mushrooms, which is part of why it has threaded through human cultures for so long.

None of this arrives without warnings, and the researchers are the first to give them. Matthew Johnson notes that even with ideal preparation at a roughly thirty milligram psilocybin dose, about a third of people report a bad trip at some point during the session. That is not a fringe risk, it is closer to a coin flip weighted toward difficulty for a meaningful share of participants.

There are rarer but sharper dangers too. Johnson confirms credible, though very rare, cases of people on psychedelics believing they could fly, including a research volunteer who tried to dive through a painting on the wall, which is exactly why supervised settings matter. And meditation researcher Richard Davidson, despite his enthusiasm for the clinical trials, is openly skeptical about handing psychedelics to otherwise healthy people, citing guides trained on little more than a one year certificate and the gap between remembering a profound experience and actually changing.

Several guests point listeners toward books rather than substances. On Joe Rogan's show, W. Bryan Hubbard urged every believing Christian to pick up A Christian's Guide to Psychedelics, saying it engages the topic chapter and verse. Elsewhere, guests have praised Sacred Knowledge by William Richards, with Hamilton Morris calling it a really good book on psychedelics and religious experience. Tim Ferriss has also mentioned publishing the classic Psilocybin: Magic Mushroom Grower's Guide under a pseudonym years ago. Reading first is the low risk way to understand the terrain before deciding anything.

Affiliate link — we may earn a commission at no extra cost to you.

Does microdosing psilocybin actually work?

According to researcher Matthew Johnson on Huberman Lab, there is no credible peer reviewed evidence that microdosing works, with studies ranging from no effect to slight cognitive impairment. Data from Robin Carhart-Harris likewise showed no benefit for depression versus two guided sessions.

Is psilocybin addictive?

Dr. Keith Humphreys told Andrew Huberman there is essentially no evidence that psilocybin or LSD are addictive, and described their abuse potential as extremely slight. That is separate from their legal status and psychological risks, which remain real.

How does psilocybin change the brain?

Huberman relays research from Carhart-Harris and Nutt showing psychedelics decrease overall brain activity while increasing global connectivity. All classic psychedelics act on the serotonin 2A receptor, according to Matthew Johnson.

So what do the experts actually say about microdosing? Broadly, that it is the weakest link in the psychedelic story, long on anecdote and short on evidence, while the real signal sits in full, supervised sessions for specific conditions. Psychedelics remain illegal in most places, they carry real psychological risk, and everything above is a report of what guests said on these shows, not medical guidance. If you are considering anything in this space, that is a conversation for a qualified doctor, not a podcast, a book, or a blog.